Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2019 Earnings Conference Call February 26, 2020 11:30 AM ET

Company Participants

Wade Walke – Vice President-Investor Relations
Brett Monia – Chief Executive Officer
Onaiza Cadoret – Chief Corporate Development and Commercial Officer
Beth Hougen – Chief Financial Officer
Richard Geary – Senior Vice President-Development
Eric Swayze – Senior Vice President-Research

Conference Call Participants

Jason Gerberry – Bank of America
Jim Birchenough – Wells Fargo
Esther Rajavelu – Openheimer
Nate Tower – Stifel
Chad Messer – Needham and Company
Vincent Chen – Bernstein
Eliana Merle – Cantor Fitzgerald
Jessica Fye – J.P. Morgan
Ross Weinreb – Goldman Sachs
Yale Jen – Laidlaw and Company
Gena Wang – Barclays

Operator

Good day, and welcome to Ionis Pharmaceuticals Q4 and Full Year 2019 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Wade Walke, Vice President, Investor Relations. Please go ahead.

Wade Walke

Thank you, Sarah. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today on the call. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website to accompany our discussion today. With me on today's call are Brett Monia, Chief Executive Officer; Onaiza Cadoret, Chief Corporate Development and Commercial Officer; Beth Hougen, our Chief Financial Officer; and Richard Geary, Senior Vice President of Development. Additionally, Eric Swayze, our Senior Vice President of Research will join us for Q&A.